Mucoadhesive Tablets Research Articles

Formulation development and evaluation of omeprazole buccal tablets

Omeprazole is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. The Mucoadhesive buccal tablets were prepared by direct compression method using Sodium Alginate, HPMC K4M and SCMC as mucoadhesive polymer. The compatibility studies of drug and excipients were performed by FT-IR spectroscopy. After examining the flow properties of the powder blends the results are found to be within prescribed limits and indicated good flowing property, hence it was subjected to tablet compression. The tablets were evaluated for post compression parameters like weight variation, hardness, thickness, friability, drug content uniformity, Surface pH, in-vitro studies like drug release. Formulation (F4) containing HPMC K4M in the ratio of (1:1) showed maximum drug release of 99.54% in 8 hrs. The drug content of shown highest of 99.61 %, Surface pH was found to be 6.05. All the evaluation parameters given the positive results and comply with the standards. The results indicate that the mucoadhesive buccal tablets of Omeprazole may be good choice to bypass the extensive hepatic first pass metabolism with an improvement in the bioavailability of Omeprazole through buccal mucosa.

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Formulation and Evaluation of Antifungal Drug Containing Mucoadhesive Tablet for Vaginal Candidiasis

Design and Development of Sertaconazole Nitrate Loaded Silver Nanoparticulate Mucoadhesive Tablets for the Treatment of Vaginal Candidiasis

Vaginal candidiasis, a fungal infection estimates that 75 % of women will be suffering at least once during their lifetime. The disorders of this infection might be premature birth, pelvic inflammation, abortion, the transmission of sexual disorders, etc. In the present research, mucoadhesive vaginal tablets containing sertaconazole nitrate-loaded silver nanoparticles formulations were developed which increases the proximity period of the medicine with the vaginal mucosa, showing sustained drug release. The drug-loaded silver nanoparticle was synthesized by the chemical reduction method. There was successful conjugation of sertaconazole nitrate with silver nanoparticles (Ser-AgNP1) therefore, the drug’s solubility is increased by 2.51 folds. The confirmation of silver nanoparticles was accessed by UV-visible spectroscopy. The mucoadhesive vaginal tablets were formulated and evaluated for swelling index, mucoadhesive force, residence time, In vitro dissolution and release kinetics, stability, and antifungal study. Optimized batch F8 was selected based on optimum mucoadhesive force (2.59±0.25N), % swelling index (86.50±0.11%), and sustained drug release (95.63±0.16%) up to 12 hr and showed greater antifungal activity. Overall study reveals that a prepared novel formulation, a mucoadhesive vaginal tablet containing sertaconazole nitrate loaded silver nanoparticles prevail over sertaconazole nitrate poor solubility and delivered drug during an extended period of time and also improved antifungal activity against Candida albicans.

Clinical and biochemical assessment of the effect of topical use of coenzyme Q10 versus topical corticosteroid in management of symptomatic oral lichen planus: randomized controlled clinical trial

BackgroundOral lichen planus (OLP) is a chronic mucocutaneous immunologically mediated condition that has a great adverse effect on oral functions. Corticosteroids are still the first drugs of choice used in the treatment of OLP; however, they have extensive medical side effects. The present study was carried out to assess the clinical therapeutic effect of the topical use of coenzyme Q10 (coQ10 or ubiquinol) versus topical corticosteroids in the management of symptomatic OLP and to determine whether the effect, if any, was due to the powerful antioxidant activity of coQ10.Subjects and methodsWe performed a randomized, double blinded controlled trial at the Faculty of Dentistry, Cairo University, Egypt. The study was conducted on 34 patients suffering from symptomatic OLP. Patients were randomly divided into two groups: intervention group (I),who received topical CoQ10 in the form of mucoadhesive tablets (40% CoQ10) 3 times daily for one month and control group (II),who received topical corticosteroid (kenacort in Orabase: triamcinolone acetonide 0.1% 5-g adhesive paste – dermapharm), 4 times daily for one month. Patients were evaluated at one-week intervals using the clinical parameters (score) of pain (VAS) and lesion size. Additionally, salivary levels of malondialdehyde (MDA) were detected in both groups before and after treatment using ELISA. All recorded data were analysed using independent t test, ANOVA followed by Bonferroni post hoc test for lesion size and salivary level of MDA data and Mann–Whitney U test and Friedman test for VAS data.ResultsBoth groups showed a significant reduction in pain and the size of the lesions (p ≤ 0.05) with no statistically significant difference between them (p > 0.05), and this clinical improvement was associated with a reduction in the salivary levels of MDA in both groups.ConclusionsThe topical use of CoQ10 mucoadhesive tablets was as effective as the topical use of triamcinolone acetonide, and its clinical effect was associated with a reduction in the salivary level of MDA.Trial registrationThe study protocol was registered at www.clinicaltrial.gov (NCT04091698) and registration date: 17/9/2019.

Development of Mucoadhesive Chitosan-Iodoacetamide Buccal Tablets for Local Delivery of Dextromethorphan

Abstract This study aimed to synthesize a chitosan (CHI) derivative, chitosan-iodoacetamide (CHI-IA), with enhanced mucoadhesive properties and develop buccal mucoadhesive tablets of CHI-IA for local delivery of dextromethorphan (DXT). Mucoadhesive CHI-IA was synthesized by a chemical reaction between CHI and iodoacetic acid (IA) in different weight ratios. The synthesized CHI-IA was characterized by Fourier-transformed infrared spectroscopy (FT-IR) and nuclear magnetic resonance spectroscopy (NMR) to confirm the chemical structure and assure successful synthesis. DXT was selected as the model drug to be incorporated into the matrix tablet to develop mucoadhesive buccal cough relief tablets. The mucoadhesive strength of the CHI-IA tablets was determined by a texture analyzer. Moreover, the drug content and the release characteristics of DXT from the mucoadhesive tablets were evaluated. The FT-IR and NMR spectra of CHI-IA indicated the conjugation of IA on the structure of CHI. The CHI-IA tablets exhibited a 4-time increase in mucoadhesion force compared with that of unmodified CHI. Moreover, a gradual release of DXT from the tablets was observed, and the release kinetics best fit with the Higuchi model (R2 = 0.9912). Therefore, the CHI-IA could be applied as the mucoadhesive carrier system for drug delivery. Keywords: Chitosan, Iodoacetic acid, Mucoadhesive, Buccal tablets, Dextromethorphan

A Review on Mucoadhesive Buccal Drug Delivery

The discovery and development of medical formulations is presently concentrated on the improvement of therapeutic drugs to be aimed at the targeted location or place to reduce total dissemination in the host. The Mucoadhesive drug delivery system is most potential therapeutic agent. The buccal route is a best route from all dosages form. In this review we study about the Mucoadhesive buccal drug there advantages, characteristics, ideal properties. The various Mucoadhesive buccal formulations. The survey on the polymer used for Mucoadhesive buccal tablets.

Formulation and evaluation of mucoadhesive fluconazole vaginal tablets

Objective: Fluconazole is a triazole antifungal agent, and is used to treat fungal infections but because of frequent dosing and undesirable side effects it affects patient compliance. There came the need for a delivery system that can skip first pass metabolism and adhere long enough to treat the infection effectively, that was the aim for this study. Mucoadhesive drug delivery system adheres to mucous membrane and provide prolonged and sustained drug release. Method: Five formulations were formed by granulation method. The granules were then compressed and tablets were formed each of 250mg. Different evaluation parameters were determined like hardness, friability, weight variation, content uniformity, mucoadhesive strength, swelling index, dissolution and compatibility analysis. Results: The hardness (7.2-8.9kg), friability (0.02-0.05%), weight variation (0.1-0.4%), content uniformity (96.9-103%), were all in the pharmacopeial range. Dissolution was determined using rotating paddle apparatus with a phosphate buffer of 6.8 pH. Release kinetics showed that F1, F2, F3 showed Fickian release while F4 showed both Fickian and non Fickian release and F5 showed non Fickian release. Mucoadhesive strength was found to be the highest (46g) in formulation F5. The highest swelling index (70.34%) was shown by formulation F3 at 12h. Differential scanning calorimeter and Fourier transform infrared spectroscopy showed that there is no interaction between excipients. Conclusion: Hence, results showed that fluconazole vaginal tablets can be formed by using these ingredients and formulation F5 was the most optimum formulation.

Formulation and evaluation of mucoadhesive fluconazole vaginal tablets

Objective: Fluconazole is a triazole antifungal agent, and is used to treat fungal infections but because of frequent dosing and undesirable side effects it affects patient compliance. There came the need for a delivery system that can skip first pass metabolism and adhere long enough to treat the infection effectively, that was the aim for this study. Mucoadhesive drug delivery system adheres to mucous membrane and provide prolonged and sustained drug release. Method: Five formulations were formed by granulation method. The granules were then compressed and tablets were formed each of 250mg. Different evaluation parameters were determined like hardness, friability, weight variation, content uniformity, mucoadhesive strength, swelling index, dissolution and compatibility analysis. Results: The hardness (7.2-8.9kg), friability (0.02-0.05%), weight variation (0.1-0.4%), content uniformity (96.9-103%), were all in the pharmacopeial range. Dissolution was determined using rotating paddle apparatus with a phosphate buffer of 6.8 pH. Release kinetics showed that F1, F2, F3 showed Fickian release while F4 showed both Fickian and non Fickian release and F5 showed non Fickian release. Mucoadhesive strength was found to be the highest (46g) in formulation F5. The highest swelling index (70.34%) was shown by formulation F3 at 12h. Differential scanning calorimeter and Fourier transform infrared spectroscopy showed that there is no interaction between excipients. Conclusion: Hence, results showed that fluconazole vaginal tablets can be formed by using these ingredients and formulation F5 was the most optimum formulation.

Bioactive Protein and Peptide Release from a Mucoadhesive Electrospun Membrane

Protein-based biologics constitute a rapidly expanding category of therapeutic agents with high target specificity. Their clinical use has dramatically increased in recent years, but administration is largely via injection. Drug delivery across the oral mucosa is a promising alternative to injections, in order to avoid the gastrointestinal tract and first-pass metabolism. Current drug delivery formulations include liquid sprays, mucoadhesive tablets and films, which lack dose control in the presence of salivary flow. To address this, electrospun membranes that adhere tightly to the oral mucosa and release drugs locally have been developed. Here, we investigated the suitability of these mucoadhesive membranes for peptide or protein release. Bradykinin (0.1%) or insulin (1, 3, and 5%) were incorporated by electrospinning from ethanol/water mixtures. Immersion of membranes in buffer resulted in the rapid release of bradykinin, with a maximal release of 70 ± 12% reached after 1 h. In contrast, insulin was liberated more slowly, with 88 ± 11, 69.0 ± 5.4, and 63.9 ± 9.0% cumulative release of the total encapsulated dose after 8 h for membranes containing 1, 3, and 5% w/w insulin, respectively. Membrane–eluted bradykinin retained pharmacological activity by inducing rapid intracellular calcium release upon binding to its cell surface receptor on oral fibroblasts, when examined by flow cytometry. To quantify further, time-lapse confocal microscopy revealed that membrane–eluted bradykinin caused a 1.58 ± 0.16 fold-change in intracellular calcium fluorescence after 10 s compared to bradykinin solution (2.13 ± 0.21), relative to placebo. In conclusion, these data show that electrospun membranes may be highly effective vehicles for site-specific administration of biotherapeutic proteins or peptides directly to the oral mucosa for either local or systemic drug delivery applications.

Efficacy of Oral Mucoadhesive N-Acetylcysteine Tablets in Treatment of Recurrent Aphthous Stomatitis: A Randomized Double-Blind, Placebo-Controlled Clinical Trial.

Objectives: This study aimed to assess the efficacy of oral mucoadhesive N-acetylcysteine (NAC) tablets for treatment of recurrent aphthous stomatitis (RAS). Materials and Methods: Forty-nine patients with RAS were randomized to receive mucoadhesive NAC tablets (n=25) or placebo (n=24). Tablets were prescribed three times a day for 7 days in each group. Pain intensity was evaluated with visual analog scale (VAS) three times a day from day 1 to day 7. Also, patients were clinically examined on days 0 (before entering the study), 3, 5, and 7 using a metal caliper to measure the diameter of the lesions. The data were statistically analyzed and P<0.05 was considered statistically significant. Results: Regarding the VAS score, all participants in the treatment group showed complete recovery on day 7 (P<0.01). Also, the diameter of the lesions was significantly smaller in the treatment group than the placebo group at the end of the study (P<0.001). Conclusion: The results of this clinical trial showed for the first time that mucoadhesive NAC tablets can significantly decrease pain and the diameter of RAS lesions without any systemic complications.

Therapeutic Potential of Naturally Modified Mucoadhesive Fluconazole Tablets against Vaginal Infection

Therapeutic Potential of Naturally Modified Mucoadhesive Fluconazole Tablets against Vaginal Infection

Atorvastatin mucoadhesive tablets in the management of recurrent aphthous stomatitis: a randomized clinical study

BackgroundAphthous stomatitis is one of the most common oral mucosal diseases. Due to the commonness of recurrent aphthous stomatitis and considering the anti-inflammatory, analgesic, and tissue regenerative properties of atorvastatin and the lack of a study on the effect of statins on minor recurrent aphthous stomatitis, this study investigates the effect of atorvastatin mucoadhesive tablets as a topical treatment on reduction of symptoms and duration of this disease.MethodsThis study is a randomized, double-blinded clinical trial. Patients were divided into two groups, atorvastatin and, placebo; each of the patients received three mucoadhesive tablets daily in the morning, noon, and night. Finally, the patients were examined on days 0 (baseline), 3, 5, and 7 to determine the diameter of the inflammatory halo. The VAS scale was used to evaluate pain intensity for up to 7 days after each meal. The data was entered into SPSS 24 software and analyzed.ResultsThe halo diameter did not significantly differ between the two groups on baseline (P > 0.05). However, on the study’s third, fifth, and seventh days, the difference between the two groups was remarkable, so in the atorvastatin group, the size of the lesions decreased in shorter healing time (P < 0.05). In addition, the patient’s pain intensity (VAS) also showed a significant decrease in the atorvastatin group except on the first, second, and seventh days of the study (P < 0.05).ConclusionAtorvastatin mucoadhesive tablets effectively reduce the pain of patients with minor recurrent aphthous stomatitis and reduce the size and healing time of the lesions, so their application should be considered in treating minor recurrent aphthous stomatitis. The present study was approved by the Medical Ethics Committee of Mazandaran University of Medical Sciences with the ethics code IR.MAZUMS.REC.1400.8346. Also, this study received code IRCT20170430033722N4.

Fabrication and Evaluation of Aceclofenac-loaded Sustained-Release Mucoadhesive Tablet Composed of Cassia fistula Seed Gum-Grafted-Poly (Sodium Acrylate)

Aim: This study was aimed to fabricate gastroretentive mucoadhesive sustained-release tablets of aceclofenac with Cassia fistula seed gum-grafted-poly(sodium acrylate) and evaluate them.&#x0D; Background: Aceclofenac has several gastric related side effects such as increase in acid secretion, gastritis, burning sensation, nausea, vomiting, etc. Sustained-release tablet may reduce these because of slow drug release. But long term use of conventional sustained-release tablets of NSAIDs showed to develop colorectal ulcer. Gastroretentive sustained-release devices may eliminate this problem.&#x0D; Objective: The objective was to synthesis Cassia fistula seed gum-grafted-poly(sodium acrylate) and apply it in the fabrication of novel mucoadhesive sustained-release tablet for aceclofenac delivery in stomach.&#x0D; Method: CFSG-grafted-poly(sodium acrylate) (CFSG-g-PSA) was synthesized by microwave-assisted free-radical initiation method using ceric ammonium nitrate (CAN) as free-radical initiator. The tablets were prepared with the graft-copolymer by wet granulation technique. Compatibility between drug and graft-copolymer was checked by FTIR, DSC and PXRD. Surface topography of the uncoated matrix tablets was studied by SEM. The tablets were evaluated for weight variation, content uniformity, dimension, disintegration test, mucoadhesive and drug-release. accelerated stability study was also done.&#x0D; Results: FTIR, DSC and PXRD studies substantiated the drug-polymer compatibility. The evaluation parameters were within prescribed limit. The study revealed excellent mucoadhesive property over 10 h and sustained-drug-release pattern following zero order kinetic. Similarity factor was found to be 83.4.&#x0D; Conclusion: The study demonstrates a simple approach of functionalization of biopolymer towards development of gastroretentive mucoadhesive sustained-release tablet formulation.

Mucoadhesive buccal tablet of leuprolide and its fatty acid conjugate: Design, in vitro evaluation and formulation strategies

This study aimed to design mucoadhesive buccal tablets of leuprolide (LEU) and to manufacture and evaluate the properties of buccal tablets containing LEU-oleic acid conjugate (LOC) and self-assembled LEU-oleic acid nanoparticles (LON), which were developed in a previous study. Hydroxypropyl methylcellulose (HPMC 4000) was used as the mucoadhesive polymer, and tablets were prepared by direct compression. The formulations were characterized by weight, content uniformity, thickness, hardness, swelling index, disintegration time, mucoadhesion time, and drug release. The chosen formulation maintained an adhesion time of up to 6.43 h and a disintegration time of 4.10 h. Drug stability in the mucoadhesive tablets was confirmed after 2 h of storage in human mimic saliva (Phosphate buffer solution pH 6.8). Furthermore, the designed LEU formulation and the LOC and LON developed in a previous study were prepared as buccal tablets and compared. In the dissolution and permeation studies, LON-loaded buccal tablets showed the highest permeation rate. This study suggests that mucoadhesive buccal tablets containing self-assembled LON may effectively increase the medication adherence for pediatric and geriatric patients by improving the bioavailability and permeation rate of LEU.

Mechanochemical Properties of Mucoadhesive Tablets Based on PVP/HPβCD Electrospun Nanofibers as Local Delivery of Polygoni cuspidati Extract for Treating Oral Infections.

This study investigated the ability of PVP/HPβCD-based electrospun nanofibers to enhance the dissolution rate of poorly soluble polydatin and resveratrol, the main active components of Polygoni cuspidati extract. To make a solid unit dosage form that would be easier to administer, extract-loaded nanofibers were ground. SEM examination was used to analyze the nanostructure of the fibers, and the results of the cross-section of the tablets showed that they had maintained their fibrous structure. The release of the active compounds (polydatin and resveratrol) in the mucoadhesive tablets was complete and prolonged in time. Additionally, the possibility of staying on the mucosa for a prolonged time has also been proven for both tablets from PVP/HPβCD-based nanofibers and powder. The appropriate physicochemical properties of the tablets, along with the proven antioxidant, anti-inflammatory, and antibacterial properties of P. cuspidati extract, highlight the particular benefits of the mucoadhesive formulation for use as a drug delivery system for periodontal diseases.

Designing and characterization of Yahom buccal mucoadhesive tablets for oral ulcer treatment

Oral ulcer is a common oral mucosal disease that affects about 5–20% of general population, particularly the elderly, and is characterized by recurrent, painful ulcerations and burning sensation. Various possible causes include local, systemic, immunologic, genetic, allergic and microorganisms. Yahom is a Thai traditional medicine that has long been used to treat nausea, vomiting, dizziness and weakness in elderly. Yahom is produced from a variety components of dried medicinal plant parts that are mostly ground into powder dosage form. Ingredients are composed of following crude drugs are common incorporated in Yahom preparations such as clove, terminalia gall, costus root and ceylon ironwood flower which practically and clearly exhibit the potent antioxidant and antimicrobial activities. Therefore, it is interesting to apply Yahom as active component for oral ulcer treatment using appropriate approach such as mucoadhesive tablet. The objective of this study is to develop buccal mucoadhesive tablet consisting of hydroxypropyl methylcellulose (HPMC) and polyvinyl pyrrolidone (PVP) as mucoadhesive polymers in formulations. The impact of various ratios of Yahom: polymer and polymer mixtures were investigated on physicochemical properties of mucoadhesive tablets were investigated including physical properties, disintegration time, water sorption/erosion behaviors and ex-vivo mucoadhesion. In addition, the antimicrobial activities of formulations against two standard microbes were also evaluated using agar cup diffusion methods. Yahom mucoadhesive tablets were successfully fabricated using direct compression tableting technique with good appearance and acceptable physical properties. Different amounts of Yahom and polymer ratios apparently influenced on water sorption, erosion behaviors and hardness of mucoadhesive tablets, resulting in alteration of disintegration time and muco-adhesion properties. In addition, these prepared tablets exhibited the efficient antimicrobial activities against Staphylococcus aureus ATCC 6538 and C. albicans ATCC 10231. Therefore, the buccal mucoadhesive tablets containing Yahom are the potential herbal delivery system for oral ulcer treatment.

Hot Melt Extrusion as an Effective Process in the Development of Mucoadhesive Tablets Containing Scutellariae baicalensis radix Extract and Chitosan Dedicated to the Treatment of Oral Infections

Hot Melt Extrusion (HME) technology was developed to obtain blends containing lyophilized Scutellariae baicalensis root extract and chitosan in order to improve the rheological properties of the obtained blends, including tableting and compressibility properties. (Hydroxypropyl)methyl cellulose (HPMC) in 3 different ratios was used as amorphous matrix formers. The systems were characterized using X-ray powder diffraction (PXRD), Fourier Transform Infrared Spectroscopy with Attenuated Total Reflectance (FTIR-ATR), and in vitro release, permeability, and microbiological activity studies. Then, the extrudates were used to prepare tablets in order to give them the appropriate pharmaceutical form. HPMC-based systems released baicalin more slowly, resulting in delayed peaks in the acceptor fluid. This behavior can be explained by the fact that HPMC swells significantly, and the dissolved substance must have diffused through the polymer network before being released. The best tabletability properties are provided by the formulation containing the extrudate with lyophilized extract HPMC 50:50 w/w. These tablets offer a valuable baicalin release profile while maintaining good mucoadhesive properties that condition the tablet's retention in the application site and the effectiveness of therapy.

Formulation and Evaluation of Mucoadhesive Tablets of Acarbose for Type 2 Diabetes

The objective of the study was to develop mucoadhesive tablet of Acarbose (α-glycosidase inhibitor) to enhance the bioavailability and to further reduce the dosing frequency of administration. The Mucoadhesive tablets of Acarbose were prepared by using three different Mucoadhesive polymers such as HPMC E5 LV, Sodium alginate and Guar Gum in varying concentrations and by direct compression technique. The micromeritics evaluation such as angle of repose, bulk density, tapped density, compressibility index and Hausner's ratio showed good to satisfactory flow properties. Swelling index was calculated with respect to time. The swelling index profile of all formulations, prepared as per the experimental design showed an increase in the value of swelling index as the amount of polymer increased. Maximum swelling index was found seen with formulations containing Sodium alginate, the value increases with increasing the amount of sodium alginate. The highest adhesion force i.e. highest strength of mucoadhesive bond was observed with Formulation F9 containing Guar gum as 18.02±0.17 this followed by F6 containing Sodium alginate as 16.33±0.56 and formulation F8 containing Guar gum in the ratio 1:2 as 14.26±0.11. The Adhesion Force increases with increasing the concentration of Mucoadhesive polymers used. The Tablets containing HPMC E5 LV showed least adhesive force than tablets of other formulations. The formulation F6 containing Sodium alginate was taken as optimized formulation based on its mucoadhesive strength and in vitro release was found to be optimum. The optimized formulation was subjected to kinetic drug release studies. The formulation best fitted into zero order kinetics. The drug release was dominated by the erosion and swelling of the polymer. From the release exponent in the Korsmeyer-Peppas model it could be suggested that the mechanism that leads to the release of drug was non-Fickian diffusion. Keywords: mucoadhesive tablet, Acarbose, Gastroretentive

Formulation of Mucoadhesive Tablets with Fully Gelatinized Modified Daluga (Cyrtosperma Merkusii) Matrix Using Simplex Lattice Design Method

starch could used as ingredient fillers, binders and crushers in tablet manufacture. Amylum is also defined as carbohydrates from from plant, as results photosynthesis, which is stored in part certain plant as backup food starch is mixture two type structure different polysaccharides that is contains (17-20) % amylose and (80-83) % amylopectin. Destination study this is for know the formulation of mucoadhesive tablets with fully gelatinized modified daluga (cyrtosperma merkusii) matrix using simplex lattice design method. Quantitative Test Methods that aim for count yield starch and qualitative tests aimed at for knowing content polysaccharides in starch. Iodine test on amylose will show color blue, and on amylopectin. Character test result data physique granules and tablets as well as release ranitidine of tablets analyzed with using the Design-Expert® software, so that obtained the contour plot of each test results. Determination of the optimum formula begins with determine the optimized parameters that is speed flow, tablet hardness, tablet friability, floating time and speed release ranitidine HCl

Formulation of Mucoadhesive Tablets with Fully Gelatinized Modified Daluga (Cyrtosperma Merkusii) Matrix Using Simplex Lattice Design Method

starch could used as ingredient fillers, binders and crushers in tablet manufacture. Amylum is also defined as carbohydrates from from plant, as results photosynthesis, which is stored in part certain plant as backup food starch is mixture two type structure different polysaccharides that is contains (17-20) % amylose and (80-83) % amylopectin. Destination study this is for know the formulation of mucoadhesive tablets with fully gelatinized modified daluga (cyrtosperma merkusii) matrix using simplex lattice design method. Quantitative Test Methods that aim for count yield starch and qualitative tests aimed at for knowing content polysaccharides in starch. Iodine test on amylose will show color blue, and on amylopectin. Character test result data physique granules and tablets as well as release ranitidine of tablets analyzed with using the Design-Expert® software, so that obtained the contour plot of each test results. Determination of the optimum formula begins with determine the optimized parameters that is speed flow, tablet hardness, tablet friability, floating time and speed release ranitidine HCl